Journal of Pediatric and Adolescent Gynecology
Volume 21, Issue 4 , Pages 171-176 , August 2008

Adolescent Female Acne: Etiology and Management

  • Yetunde Olutunmbi, BA

      Affiliations

    • School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    • ,
  • Kristina Paley, MD

      Affiliations

    • Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    • ,
  • Joseph C. English III, MD

      Affiliations

    • Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    • Corresponding Author InformationAddress correspondence to: Joseph C. English III, MD, Department of Dermatology, University of Pittsburgh Medical Center, Suite 145 Lothrop Hall, 190 Lothrop St,. Pittsburgh, PA 15213

References 

  1. White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol. 1998;39:S34
  2. Sathakis V, Kilkenny M, Marks R. Descriptive epidemiology of acne vulgaris in the community. Australas J Dermatol. 1997;38:115
  3. Lehmann HP, Robinson K, Andrews , et al. Acne therapy: a methodologic review. J Am Acad Dermatol. 2002;47:231
  4. James WD, Berger TG, Elston DM. Andrews' Diseases of the Skin. Clinical Dermatology. 9th ed.. Philadelphia: Saunders; 2000;
  5. Bataille V, Sneider H, MacGregor AJ, et al. The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. J Invest Dermatol. 2002;119:1317
  6. Yosipovitch G, Tang M, Dawn AG, et al. Study of psychological stress, sebum production and acne vulgaris in adolescents. Acta Derm Venereol. 2007;87:135
  7. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med. 2000;9:179
  8. Adebamowo CA, Spiegelman D, Danby FW, et al. High school dietary dairy intake and teenage acne. J Am Acad Dermatol. 2005;52:207
  9. Thiboutot D, Gillialand K, Light J, et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol. 1999;135:1041
  10. Cibula D, Hill M, Vohradnikova O, et al. The role of androgens in determining acne severity in adult women. Br J Dermatol. 2000;143:399
  11. Khoiny FE. Use of depo-provera in teens. J Pediatr Health Care. 1996;10(5):195
  12. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:513
  13. Chi IC. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs. Contraception. 1991;44:573
  14. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651
  15. Escobar-Morreale HF. Macroprolactinemia in women presenting with hyperandrogenic symptoms: implications for the management of polycystic ovary syndrome. Fertil Steril. 2004;82:1697
  16. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292:726
  17. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54:73
  18. Glass D, Boorman GC, Stables GI, et al. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatol. 1999;199:242
  19. Zouboulis CC, Derumeaux L, Decroix J, et al. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol. 2000;143:498
  20. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997;37:590
  21. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;11:209
  22. Muhlemann MF, Carter GD, Cream JJ, et al. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227
  23. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol. 2002;57:231
  24. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, et al. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception. 1999;60:255
  25. Arowojolu AO, Gallo MF, Lopez LM, et al. Combined oral contraceptive pills for treatment of acne: Review. Cochrane Database Syst Rev. 2007;24(1):CD004425
  26. Rabe T, Kowald A, Ortmann J, et al. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000;14:223
  27. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89:615
  28. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997;37:746
  29. Maloney M, Arbit DI, Flack M, et al. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Womens Health. 2001;2:123
  30. Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception. 2006;73:23
  31. Thioboutot D, Archer DF, Lemay A, et al. A randomized, controlled trial of a low-dose contraceptive containing 20 ug of ethinyl estradiol and 100ug of levonorgestrel for acne treatment. Fertil Steril. 2001;76:461
  32. Leyden J, Shalita A, Hordinsky M, et al. Efficacy of a low-dose oral contraceptive containing 20μg of ethinyl estradiol and 100 μg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. J Am Acad Dermatol. 2002;47:399
  33. Rapkin AJ, Winer SA. Drospirenone: a novel progestin. Expert Opin Pharmacother. 2007;8:989
  34. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74:123
  35. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43:498
  36. Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation and therapies. Sem Cutan Med Surg. 2001;20:144
  37. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: A randomized trial of 20 μg and 35 μg estrogen preparations. Contraception. 2000;60:32
  38. Sherif K. Benefits and risks of oral contraceptives. Am J Obstet Gyn. 1999;180:343
  39. Lidegaard O. Smoking and use of oral contraceptives: Impact on thrombotic diseases. Am J Obstet Gyn. 1999;180:357

PII: S1083-3188(07)00248-3

doi: 10.1016/j.jpag.2007.07.004

Journal of Pediatric and Adolescent Gynecology
Volume 21, Issue 4 , Pages 171-176 , August 2008

Article Tools

* Image Usage & Resolution